JP2012019788A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012019788A5 JP2012019788A5 JP2011156396A JP2011156396A JP2012019788A5 JP 2012019788 A5 JP2012019788 A5 JP 2012019788A5 JP 2011156396 A JP2011156396 A JP 2011156396A JP 2011156396 A JP2011156396 A JP 2011156396A JP 2012019788 A5 JP2012019788 A5 JP 2012019788A5
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- polypeptide
- disease
- nucleic acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims 48
- 108090000765 processed proteins & peptides Proteins 0.000 claims 48
- 210000001519 tissue Anatomy 0.000 claims 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 22
- 108020004707 nucleic acids Proteins 0.000 claims 13
- 102000039446 nucleic acids Human genes 0.000 claims 13
- 150000007523 nucleic acids Chemical class 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 208000035475 disorder Diseases 0.000 claims 12
- 239000000523 sample Substances 0.000 claims 11
- 230000004069 differentiation Effects 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 150000001413 amino acids Chemical group 0.000 claims 9
- 241000124008 Mammalia Species 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 230000017423 tissue regeneration Effects 0.000 claims 6
- 238000011282 treatment Methods 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 5
- 239000012634 fragment Substances 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- 208000020084 Bone disease Diseases 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 4
- 238000000576 coating method Methods 0.000 claims 4
- 230000003412 degenerative effect Effects 0.000 claims 4
- 230000009261 transgenic effect Effects 0.000 claims 4
- 230000005779 cell damage Effects 0.000 claims 3
- 208000037887 cell injury Diseases 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 206010014561 Emphysema Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 2
- 208000022555 Genital disease Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000005013 brain tissue Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000000845 cartilage Anatomy 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 210000002808 connective tissue Anatomy 0.000 claims 2
- 210000004268 dentin Anatomy 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 230000003394 haemopoietic effect Effects 0.000 claims 2
- 210000005003 heart tissue Anatomy 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 230000007954 hypoxia Effects 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 230000005865 ionizing radiation Effects 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 230000008520 organization Effects 0.000 claims 2
- 230000002611 ovarian Effects 0.000 claims 2
- 208000028169 periodontal disease Diseases 0.000 claims 2
- 230000003239 periodontal effect Effects 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- 210000005084 renal tissue Anatomy 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 208000020431 spinal cord injury Diseases 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 230000002792 vascular Effects 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 238000005481 NMR spectroscopy Methods 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 238000000333 X-ray scattering Methods 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 229940125721 immunosuppressive agent Drugs 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 238000002513 implantation Methods 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 150000003951 lactams Chemical class 0.000 claims 1
- 150000002596 lactones Chemical class 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004949 mass spectrometry Methods 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 230000008410 smoothened signaling pathway Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000002381 testicular Effects 0.000 claims 1
- 210000001550 testis Anatomy 0.000 claims 1
- 238000011830 transgenic mouse model Methods 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58051104P | 2004-06-17 | 2004-06-17 | |
| US60/580,511 | 2004-06-17 | ||
| US60862504P | 2004-09-10 | 2004-09-10 | |
| US60/608,625 | 2004-09-10 | ||
| US61005404P | 2004-09-15 | 2004-09-15 | |
| US60/610,054 | 2004-09-15 | ||
| US61873504P | 2004-10-14 | 2004-10-14 | |
| US60/618,735 | 2004-10-14 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516772A Division JP4971149B2 (ja) | 2004-06-17 | 2005-06-17 | Ｔｄｆ関連化合物およびその類似体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012193673A Division JP5829193B2 (ja) | 2004-06-17 | 2012-09-04 | Ｔｄｆ関連化合物およびその類似体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012019788A JP2012019788A (ja) | 2012-02-02 |
| JP2012019788A5 true JP2012019788A5 (enExample) | 2012-10-04 |
| JP5513449B2 JP5513449B2 (ja) | 2014-06-04 |
Family
ID=35785692
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516772A Expired - Fee Related JP4971149B2 (ja) | 2004-06-17 | 2005-06-17 | Ｔｄｆ関連化合物およびその類似体 |
| JP2011156396A Expired - Fee Related JP5513449B2 (ja) | 2004-06-17 | 2011-07-15 | Ｔｄｆ関連化合物およびその類似体 |
| JP2012193673A Expired - Fee Related JP5829193B2 (ja) | 2004-06-17 | 2012-09-04 | Ｔｄｆ関連化合物およびその類似体 |
| JP2014191625A Pending JP2015013894A (ja) | 2004-06-17 | 2014-09-19 | Ｔｄｆ関連化合物およびその類似体 |
| JP2016093053A Withdrawn JP2016155855A (ja) | 2004-06-17 | 2016-05-06 | Ｔｄｆ関連化合物およびその類似体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007516772A Expired - Fee Related JP4971149B2 (ja) | 2004-06-17 | 2005-06-17 | Ｔｄｆ関連化合物およびその類似体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012193673A Expired - Fee Related JP5829193B2 (ja) | 2004-06-17 | 2012-09-04 | Ｔｄｆ関連化合物およびその類似体 |
| JP2014191625A Pending JP2015013894A (ja) | 2004-06-17 | 2014-09-19 | Ｔｄｆ関連化合物およびその類似体 |
| JP2016093053A Withdrawn JP2016155855A (ja) | 2004-06-17 | 2016-05-06 | Ｔｄｆ関連化合物およびその類似体 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8410246B2 (enExample) |
| EP (3) | EP1773871B1 (enExample) |
| JP (5) | JP4971149B2 (enExample) |
| AU (1) | AU2005265098B2 (enExample) |
| CA (2) | CA2897218A1 (enExample) |
| WO (1) | WO2006009836A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005265098B2 (en) | 2004-06-17 | 2012-02-23 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
| EP3117833B1 (en) * | 2005-07-19 | 2019-01-23 | Stemgen S.P.A. | Inhibition of the tumorigenic potential of tumor stem cells by lif |
| HUE026634T2 (en) * | 2005-09-20 | 2016-07-28 | Thrasos Innovation Inc | TDF-related compounds and analogues thereof |
| AU2012201060B2 (en) * | 2005-09-20 | 2015-01-22 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
| WO2008150550A1 (en) * | 2007-06-05 | 2008-12-11 | Cornell University | Compounds for enhancing p21 expression and methods of use thereof |
| DE102007045957A1 (de) | 2007-09-26 | 2009-04-09 | Bayer Cropscience Ag | Wirkstoffkombinationen mit insektiziden und akarziden Eigenschaften |
| DE102007045919B4 (de) | 2007-09-26 | 2018-07-05 | Bayer Intellectual Property Gmbh | Wirkstoffkombinationen mit insektiziden und akariziden Eigenschaften |
| DE102007045956A1 (de) | 2007-09-26 | 2009-04-09 | Bayer Cropscience Ag | Wirkstoffkombination mit insektiziden und akariziden Eigenschaften |
| US9719068B2 (en) | 2010-05-06 | 2017-08-01 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
| CA2842330A1 (en) * | 2011-07-19 | 2013-01-24 | Thrasos Innovation, Inc. | Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis |
| EP3149156B1 (en) | 2014-05-28 | 2021-02-17 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
| WO2016010844A1 (en) * | 2014-07-14 | 2016-01-21 | Tarix Pharmaceuticals Ltd | Methods and compositions for the treatment of stroke |
| JP6804438B2 (ja) | 2014-10-17 | 2020-12-23 | チルドレンズ ホスピタル メディカル センター | 多能性幹細胞を使用するヒト小腸のｉｎ ｖｉｖｏモデル、並びにそれを作製、及び使用する方法 |
| WO2016077539A1 (en) * | 2014-11-12 | 2016-05-19 | Thrasos Innovation, Inc. | Peptides with enhanced stability and their use in methods for treating diseases |
| CN109311956A (zh) | 2015-08-25 | 2019-02-05 | 伊斯迪德股份公司 | 诱导组织形成的化合物及其应用 |
| EP3349782A2 (en) * | 2015-09-17 | 2018-07-25 | Histide AG | Pharmaceutical association comprising a growth factor receptor agonist conjugated to a bioactive carrier for converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| EP3349777B1 (en) * | 2015-09-17 | 2025-05-07 | Histide AG | Pharmaceutical association comprising a growth factor receptor agonist conjugated to a bioactive carrierfor converting a neoplastic cell into a non-neoplastic cell and uses thereof |
| WO2017178253A1 (en) * | 2016-04-13 | 2017-10-19 | Universiteit Maastricht | Method for the treatment or prevention of osteoarthritis |
| EP4177335A1 (en) | 2016-05-05 | 2023-05-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
| EP3534976A4 (en) | 2016-11-04 | 2020-09-16 | Children's Hospital Medical Center | PATHOLOGICAL MODELS OF HEPATIC ORGANOIDS AND ASSOCIATED METHODS OF MANUFACTURE AND USE |
| EP3548507A4 (en) | 2016-12-05 | 2020-07-15 | Children's Hospital Medical Center | COLON ORGANOIDS AND PROCESSES FOR THE PREPARATION AND USE THEREOF |
| US10767164B2 (en) | 2017-03-30 | 2020-09-08 | The Research Foundation For The State University Of New York | Microenvironments for self-assembly of islet organoids from stem cells differentiation |
| EP3609997A4 (en) | 2017-04-14 | 2021-03-03 | Children's Hospital Medical Center | COMPOSITIONS OF STEM CELLS FROM MULTIPLE DONOR CELLS AND THEIR PREPARATION PROCEDURES |
| KR101822633B1 (ko) * | 2017-08-22 | 2018-01-26 | (주)진셀팜 | 폴리스타틴 유래 생리활성 펩타이드, 및 이의 용도 |
| EP3694603A4 (en) | 2017-10-10 | 2021-07-14 | Children's Hospital Medical Center | ESOPHAGUS TISSUE AND / OR ORGANOID COMPOSITIONS AND METHOD FOR MANUFACTURING THEREOF |
| US12379372B2 (en) | 2017-12-21 | 2025-08-05 | Children's Hospital Medical Center | Digitalized human organoids and methods of using same |
| KR102887406B1 (ko) | 2018-07-26 | 2025-11-19 | 칠드런즈 호스피탈 메디칼 센터 | 간-담도-췌장 조직 및 이를 제조하는 방법 |
| WO2020056158A1 (en) | 2018-09-12 | 2020-03-19 | Children's Hospital Medical Center | Organoid compositions for the production of hematopoietic stem cells and derivatives thereof |
| EP4595974A3 (en) | 2018-10-22 | 2025-08-13 | William D. Carlson | Therapeutic combinations of tdfrps and additional agents and methods of use |
| EP3981431A4 (en) * | 2019-03-14 | 2023-06-28 | Rena Therapeutics Inc. | Nucleic acid complex for modulating ihh expression |
| WO2022020711A1 (en) * | 2020-07-24 | 2022-01-27 | The Texas A&M University System | Sars-cov-2 main protease inhibitors |
| CA3212468A1 (en) * | 2021-03-16 | 2022-09-22 | William D. Carlson | Therapeutic combinations of tdfrps and additional agents and methods of use for the reversal of fibrosis |
| CN116286643A (zh) * | 2021-03-26 | 2023-06-23 | 广西大学 | 一种体外高效诱导人体细胞重编程为神经元细胞的方法 |
| WO2024081245A1 (en) | 2022-10-10 | 2024-04-18 | Therapeutics By Design, LLC | Tissue differentiation factor related polypeptides (tdfrps) for the treatment of myocardial injury |
| CN117045795A (zh) * | 2023-08-11 | 2023-11-14 | 中南大学湘雅三医院 | 一种Hedgehog通路抑制剂在防治动脉搭桥术后并发症的制药用途 |
Family Cites Families (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4391909A (en) | 1979-03-28 | 1983-07-05 | Damon Corporation | Microcapsules containing viable tissue cells |
| US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
| US4768523A (en) | 1981-04-29 | 1988-09-06 | Lifecore Biomedical, Inc. | Hydrogel adhesive |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4870009A (en) | 1982-11-22 | 1989-09-26 | The Salk Institute For Biological Studies | Method of obtaining gene product through the generation of transgenic animals |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4736866B1 (en) | 1984-06-22 | 1988-04-12 | Transgenic non-human mammals | |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| JP2874751B2 (ja) | 1986-04-09 | 1999-03-24 | ジェンザイム・コーポレーション | 希望する蛋白質をミルク中へ分泌する遺伝子移植動物 |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5041138A (en) | 1986-11-20 | 1991-08-20 | Massachusetts Institute Of Technology | Neomorphogenesis of cartilage in vivo from cell culture |
| GB8630273D0 (en) | 1986-12-18 | 1987-01-28 | Til Medical Ltd | Pharmaceutical delivery systems |
| US5041126A (en) | 1987-03-13 | 1991-08-20 | Cook Incorporated | Endovascular stent and delivery system |
| US5092871A (en) | 1987-03-13 | 1992-03-03 | Brown University Research Foundation | Electrically-charged nerve guidance channels |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
| US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
| US5106627A (en) | 1987-11-17 | 1992-04-21 | Brown University Research Foundation | Neurological therapy devices |
| US5213580A (en) | 1988-08-24 | 1993-05-25 | Endoluminal Therapeutics, Inc. | Biodegradable polymeric endoluminal sealing process |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US4955892A (en) | 1988-10-24 | 1990-09-11 | Louisiana State University | Neural cell adhesion protein nerve prosthesis |
| US5089606A (en) | 1989-01-24 | 1992-02-18 | Minnesota Mining And Manufacturing Company | Water-insoluble polysaccharide hydrogel foam for medical applications |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| JPH085780B2 (ja) | 1989-04-28 | 1996-01-24 | 呉羽化学工業株式会社 | 変形性関節症治療剤 |
| DE69033493D1 (de) | 1989-07-25 | 2004-08-12 | Cell Genesys Inc | Homologe rekombination für universelle donorzellen und chimerische säugetierzellen |
| US5439446A (en) | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
| US5052998A (en) | 1990-04-04 | 1991-10-01 | Zimmon David S | Indwelling stent and method of use |
| US5064435A (en) | 1990-06-28 | 1991-11-12 | Schneider (Usa) Inc. | Self-expanding prosthesis having stable axial length |
| IL98764A0 (en) | 1990-07-10 | 1992-07-15 | Smithkline Beecham Corp | Oxamides |
| AU1570292A (en) | 1991-02-07 | 1992-09-07 | Board Of Trustees Of The University Of Illinois, The | Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same |
| DE69231946T2 (de) | 1991-03-11 | 2002-04-04 | Curis, Inc. | Protein-induzierende morphogenese |
| US5147370A (en) | 1991-06-12 | 1992-09-15 | Mcnamara Thomas O | Nitinol stent for hollow body conduits |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| JP3693338B2 (ja) | 1991-08-30 | 2005-09-07 | キュリス インコーポレイテッド | 組織形成因子誘導による炎症反応の調節 |
| ES2253736T3 (es) | 1991-08-30 | 2006-06-01 | Curis, Inc. | Tratamiento para prevenir la perdida y/o aumentar la masa osea en transtornos metabolicos del hueso. |
| US5525519A (en) | 1992-01-07 | 1996-06-11 | Middlesex Sciences, Inc. | Method for isolating biomolecules from a biological sample with linear polymers |
| US5176626A (en) | 1992-01-15 | 1993-01-05 | Wilson-Cook Medical, Inc. | Indwelling stent |
| US5683448A (en) | 1992-02-21 | 1997-11-04 | Boston Scientific Technology, Inc. | Intraluminal stent and graft |
| US5233409A (en) | 1992-02-25 | 1993-08-03 | Schwab Karl W | Color analysis of organic constituents in sedimentary rocks for thermal maturity |
| AU681594B2 (en) | 1992-07-31 | 1997-09-04 | Stryker Corporation | Morphogen-induced nerve regeneration and repair |
| AU682154B2 (en) | 1992-09-15 | 1997-09-25 | Creative Biomolecules, Inc. | Morphogen treatment of gastrointestinal ulcers |
| AU681356B2 (en) | 1992-09-16 | 1997-08-28 | Stryker Corporation | Morphogen-induced liver regeneration |
| DE69333366T2 (de) | 1992-10-30 | 2004-09-16 | The General Hospital Corp., Boston | Ein neues zellzyklus kontrollprotein |
| AU683431B2 (en) | 1992-11-17 | 1997-11-13 | Ludwig Institute For Cancer Research | Activin receptor-like kinases, proteins having serine/ threonine kinase domains and their use |
| US5579591A (en) | 1993-06-29 | 1996-12-03 | Limited Responsibility Company Frontier | Footwear for patients of osteoarthritis of the knee |
| CA2179029C (en) | 1993-12-30 | 2009-02-24 | Philip W. Ingham | Vertebrate embryonic pattern-inducing hedgehog-like proteins |
| ATE378407T1 (de) | 1994-04-29 | 2007-11-15 | Curis Inc | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen |
| US5614609A (en) | 1994-10-20 | 1997-03-25 | Carlos F. Ibanez | Serine threonine kinase receptor |
| US6306622B1 (en) | 1994-11-04 | 2001-10-23 | The Procter & Gamble Co. | cDNA encoding a BMP type II receptor |
| US6210899B1 (en) | 1994-11-04 | 2001-04-03 | The Procter & Gamble Company | Use of a BMP protein receptor complex for screening bone metabolism actives and cells co-transfected with a type II BMP receptor and type I BMP receptor |
| US6281332B1 (en) | 1994-12-02 | 2001-08-28 | The Johns Hopkins University School Of Medicine | Hedgehog-derived polypeptides |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US5681274A (en) | 1995-03-31 | 1997-10-28 | Boston Scientific Corporation | Variable length uretheral stent |
| US5569676A (en) | 1995-05-24 | 1996-10-29 | Diehl; Harry W. | Method for the treatment of osteoarthritis |
| WO1997007135A2 (en) | 1995-08-14 | 1997-02-27 | Creative Biomolecules, Inc. | Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof |
| US5989827A (en) | 1995-11-14 | 1999-11-23 | Abbott Laboratories | Use of nuclear magnetic resonance to design ligands to target biomolecules |
| JP2000501744A (ja) * | 1996-01-22 | 2000-02-15 | クリエイティブ バイオモレキゥルズ，インコーポレーテッド | モルホゲン類似体およびその製法 |
| US20030185792A1 (en) * | 1996-01-22 | 2003-10-02 | Curis, Inc. | Morphogen analogs of bone morphogenic proteins |
| US6214796B1 (en) | 1996-03-22 | 2001-04-10 | The General Hospital Corporation | Administration of polypeptide growth factors following central nervous system ischemia or trauma |
| CA2283356C (en) | 1997-03-07 | 2009-06-30 | Mount Sinai Hospital | Methods to diagnose a required regulation of trophoblast invasion |
| US6818440B2 (en) | 1997-04-28 | 2004-11-16 | Sugen, Inc. | Diagnosis and treatment of alk-7 related disorders |
| US6111066A (en) | 1997-09-02 | 2000-08-29 | Martek Biosciences Corporation | Peptidic molecules which have been isotopically substituted with 13 C, 15 N and 2 H in the backbone but not in the sidechains |
| US6198281B1 (en) | 1997-11-12 | 2001-03-06 | The Research Foundation Of State University Of New York | NMR spectroscopy of large proteins |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP3561738B2 (ja) | 1998-06-02 | 2004-09-02 | 株式会社リガク | Ｂｒａｇｇ反射自動選出方法および装置並びに結晶方位自動決定方法およびシステム |
| CA2336220A1 (en) | 1998-07-24 | 2000-02-03 | The Carnegie Institution Of Washington | Method for maintenance and propagation of germline stem cells using members of the tgf-.beta. family of growth factors |
| JP2002524528A (ja) | 1998-09-11 | 2002-08-06 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | ヘッジホッグ様ポリペプチドによる肺組織の調節、およびそれに関する製剤および使用方法 |
| US6329184B1 (en) | 1998-12-18 | 2001-12-11 | Pharmacia & Upjohn Ab | Crystalline form of activated tartrate-resistant and purple acid phosphatase |
| US6444802B1 (en) * | 1999-09-30 | 2002-09-03 | Millenium Pharmaceuticals, Inc. | Human aminopeptidase |
| US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| US6468346B2 (en) | 1999-12-10 | 2002-10-22 | Bsi Proteomics Corporation | Applying x-ray topography and diffractometry to improve protein crystal growth |
| US20040171533A1 (en) | 2000-02-29 | 2004-09-02 | Barbara Zehentner | Methods and compositions for regulating adiopocytes |
| US6669722B2 (en) | 2000-09-22 | 2003-12-30 | Cordis Corporation | Stent with optimal strength and radiopacity characteristics |
| EP1334442A2 (en) | 2000-11-06 | 2003-08-13 | Thrasos, Inc. | Computer method and apparatus for classifying objects |
| DE60033576T2 (de) | 2000-11-06 | 2007-10-31 | Thrasos, Inc., Waltham | Methoden zum screening knochenmorphogenetishemimetika |
| US20040031066A9 (en) | 2001-01-18 | 2004-02-12 | Faustman Denise L. | Mouse model for rheumatoid arthritis |
| US6679911B2 (en) | 2001-03-01 | 2004-01-20 | Cordis Corporation | Flexible stent |
| EP1383867A2 (en) | 2001-03-23 | 2004-01-28 | Axordia Limited | Stem cell differentiation |
| US6673106B2 (en) | 2001-06-14 | 2004-01-06 | Cordis Neurovascular, Inc. | Intravascular stent device |
| US20030103959A1 (en) | 2001-06-22 | 2003-06-05 | Hughes Paul E. | Methods of providing neuroprotection and/or neurorestoration via the neural activin type IIB receptor |
| WO2003106972A2 (en) | 2002-06-17 | 2003-12-24 | Thrasos, Inc. | Multiple domain tdf-related compounds and analogs thereof |
| ES2397327T3 (es) * | 2002-06-17 | 2013-03-06 | Thrasos, Inc. | Compuestos asociados a un dominio único de TDF y análogos de los mismos |
| US20040093164A1 (en) * | 2002-11-08 | 2004-05-13 | Carlson William D. | Computer system and methods for producing morphogen analogs of human TDF-1 |
| AU2005265098B2 (en) | 2004-06-17 | 2012-02-23 | Thrasos Innovation, Inc. | TDF-related compounds and analogs thereof |
| GB0414093D0 (en) | 2004-06-23 | 2004-07-28 | Glaxo Group Ltd | Novel compounds |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
-
2005
- 2005-06-17 AU AU2005265098A patent/AU2005265098B2/en not_active Ceased
- 2005-06-17 CA CA2897218A patent/CA2897218A1/en not_active Abandoned
- 2005-06-17 CA CA2571218A patent/CA2571218C/en not_active Expired - Fee Related
- 2005-06-17 EP EP05762534.5A patent/EP1773871B1/en not_active Expired - Lifetime
- 2005-06-17 JP JP2007516772A patent/JP4971149B2/ja not_active Expired - Fee Related
- 2005-06-17 EP EP10182714A patent/EP2319526A1/en not_active Withdrawn
- 2005-06-17 EP EP20140167540 patent/EP2789342A1/en not_active Withdrawn
- 2005-06-17 US US11/629,558 patent/US8410246B2/en not_active Expired - Fee Related
- 2005-06-17 WO PCT/US2005/021444 patent/WO2006009836A2/en not_active Ceased
-
2011
- 2011-07-15 JP JP2011156396A patent/JP5513449B2/ja not_active Expired - Fee Related
-
2012
- 2012-09-04 JP JP2012193673A patent/JP5829193B2/ja not_active Expired - Fee Related
-
2013
- 2013-02-26 US US13/777,658 patent/US8916686B2/en not_active Expired - Fee Related
-
2014
- 2014-09-19 JP JP2014191625A patent/JP2015013894A/ja active Pending
- 2014-11-12 US US14/539,417 patent/US9181301B2/en not_active Expired - Fee Related
-
2015
- 2015-10-02 US US14/873,264 patent/US20160152674A1/en not_active Abandoned
-
2016
- 2016-05-06 JP JP2016093053A patent/JP2016155855A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012019788A5 (enExample) | ||
| JP2014132900A5 (enExample) | ||
| JP2012149081A5 (enExample) | ||
| Terrell et al. | Calcium’s role and signaling in aging muscle, cellular senescence, and mineral interactions | |
| SA515360253B1 (ar) | أجسام مضادة مُميزة لألفا سينوكلين | |
| EP2900263B1 (en) | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15) | |
| RU2421465C2 (ru) | Антитела к рецептору igf-i | |
| Zhu et al. | Mesenchymal stem cell-secreted soluble signaling molecules potentiate tumor growth | |
| JP2010501163A5 (enExample) | ||
| JP6757712B2 (ja) | 幹細胞増強治療法 | |
| EP2928494A1 (en) | A METHOD OF REDUCING BRAIN AMYLOID PLAQUES USING ANTI-Aß ANTIBODIES | |
| UA123862C2 (uk) | Моноклональне антитіло, специфічне до гіперфосфорилованого тау-білка, і спосіб його застосування | |
| KR20190138672A (ko) | 항 igf-i 수용체 항체 | |
| TW201900682A (zh) | 抗ｐｈｆ－ｔａｕ抗體及其用途 | |
| RU2017107773A (ru) | Антитела, специфичные к ммр9 | |
| EP2033971A1 (de) | Bone Morphogenetic Protein (BMP)-bindende Domänen von Proteinen der Repulsive Guidance Molecule (RGM) Proteinfamilie und funktionale Fragmente davon sowie deren Verwendung | |
| KR20140027051A (ko) | 인간 프로스타글란딘 e2 수용체 ep4 에 대한 항체 | |
| TW201335188A (zh) | 抗－ｃｘｃｒ３抗體 | |
| JP2019520034A5 (enExample) | ||
| CN103648531A (zh) | 用于预防或治疗代谢综合症的方法 | |
| JP2016514099A5 (enExample) | ||
| WO2013026334A1 (zh) | 阻止细胞dna合成、抑制细胞增殖的多肽及其用途 | |
| JP2014515600A5 (enExample) | ||
| JP2009508532A5 (enExample) | ||
| US8906864B2 (en) | Binding domains of proteins of the repulsive guidance molecule (RGM) protein family and functional fragments thereof, and their use |